MX365308B - Fármaco de formulación de ion de sodio e ion de calcio para el tratamiento de cáncer, tumores y tumores no malignos. - Google Patents

Fármaco de formulación de ion de sodio e ion de calcio para el tratamiento de cáncer, tumores y tumores no malignos.

Info

Publication number
MX365308B
MX365308B MX2014006746A MX2014006746A MX365308B MX 365308 B MX365308 B MX 365308B MX 2014006746 A MX2014006746 A MX 2014006746A MX 2014006746 A MX2014006746 A MX 2014006746A MX 365308 B MX365308 B MX 365308B
Authority
MX
Mexico
Prior art keywords
tumor
treating cancer
malignancy
methods
pharmaceutical compositions
Prior art date
Application number
MX2014006746A
Other languages
English (en)
Other versions
MX2014006746A (es
Inventor
l liu David
Original Assignee
l liu David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by l liu David filed Critical l liu David
Publication of MX2014006746A publication Critical patent/MX2014006746A/es
Publication of MX365308B publication Critical patent/MX365308B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a una composición farmacéutica formulada única y a un nuevo método de tratamiento de inyección intratumoral. La composición farmacéutica de la invención es la solución iónica saturada de iones de sodio y iones de calcio (la "bomba medicinal de iones"). La invención de la inyección intratumoral con la "bomba medicinal de iones" puede utilizarse como tratamiento de primera línea para tratar cáncer y tumor en nueve órganos humanos (carcinoma y tumor de la piel y tejido subcutáneo, de mama, próstata, tiroides, pulmón, hígado, órgano genital, cerebro y páncreas) y ciertas otras enfermedades benignas (neoplasia de piel y7 subcutánea, cambio fibroquístico de mama, hiperplasia prostática benigna y nódulos de tiroides).
MX2014006746A 2011-12-04 2012-12-04 Fármaco de formulación de ion de sodio e ion de calcio para el tratamiento de cáncer, tumores y tumores no malignos. MX365308B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566655P 2011-12-04 2011-12-04
PCT/US2012/067802 WO2013133873A2 (en) 2011-12-04 2012-12-04 Pharmaceutical compositions of sodium ion and calcium ion and methods for treating cancer, tumor and non-malignancy

Publications (2)

Publication Number Publication Date
MX2014006746A MX2014006746A (es) 2016-02-10
MX365308B true MX365308B (es) 2019-05-29

Family

ID=49117478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006746A MX365308B (es) 2011-12-04 2012-12-04 Fármaco de formulación de ion de sodio e ion de calcio para el tratamiento de cáncer, tumores y tumores no malignos.

Country Status (9)

Country Link
US (1) US9962403B2 (es)
EP (1) EP2785357A4 (es)
JP (2) JP2015500286A (es)
CN (1) CN104244959B (es)
BR (1) BR112014013561B1 (es)
IN (1) IN2014KN01391A (es)
MX (1) MX365308B (es)
RU (1) RU2600166C2 (es)
WO (1) WO2013133873A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
CN113433307A (zh) * 2020-02-10 2021-09-24 安派科生物医学科技有限公司 用于疾病检测和治疗的新型仪器和方法
CN114984040A (zh) * 2021-04-28 2022-09-02 黄永茂 调理人体经络生物电的适度氯化氢组分及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224349A (en) * 1978-11-17 1980-09-23 Gooch Robert C Meat tenderizing method
WO1996023512A1 (en) * 1995-02-03 1996-08-08 Les Laboratoires Aeterna Inc. Extracts of shark cartilage, process of production and uses thereof
US6734018B2 (en) * 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
CN1159016C (zh) * 2001-07-02 2004-07-28 卜子英 一种注射用治疗实体性肿瘤的药物组合物
CN101209344B (zh) * 2006-12-28 2012-07-04 赵超英 高渗液组合物在制备促进伤口愈合的药物中的应用

Also Published As

Publication number Publication date
RU2014127148A (ru) 2016-02-10
EP2785357A4 (en) 2015-08-26
JP2015500286A (ja) 2015-01-05
WO2013133873A2 (en) 2013-09-12
IN2014KN01391A (es) 2015-10-23
BR112014013561B1 (pt) 2019-04-24
CN104244959B (zh) 2019-01-04
US20140322359A1 (en) 2014-10-30
JP2017061554A (ja) 2017-03-30
WO2013133873A3 (en) 2014-02-20
JP6659525B2 (ja) 2020-03-04
RU2600166C2 (ru) 2016-10-20
US9962403B2 (en) 2018-05-08
EP2785357A2 (en) 2014-10-08
CN104244959A (zh) 2014-12-24
BR112014013561A2 (pt) 2016-09-20
MX2014006746A (es) 2016-02-10

Similar Documents

Publication Publication Date Title
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
BRPI0507039A8 (pt) composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
EA201391286A1 (ru) Лечение солидных опухолей
TW201613589A (en) Combination methods for treating cancers
UA116007C2 (uk) Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
HK1123186A1 (en) Combination of zd6474 and pemetrexed zd6474
BRPI0810384B8 (pt) terapia enzimática anticâncer
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
MX365308B (es) Fármaco de formulación de ion de sodio e ion de calcio para el tratamiento de cáncer, tumores y tumores no malignos.
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
BRPI0508959A (pt) uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
HK1089384A1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
NO20064754L (no) Kombinasjonsterapi
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
MX2022003044A (es) Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
Tanigawa RFA of metastatic bone tumors
NZ709685A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
BR0315087A (pt) Métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6126 ou um sal deste farmaceuticamente aceitável e gencitabina

Legal Events

Date Code Title Description
FG Grant or registration